MRI of hypertrophic cardiomyopathy: Part 2. differential diagnosis, risk stratification, and posttreatment MRI appearances

被引：31

作者：

Hansen, Mark W.

Merchant, Naeem

机构：

[1] Prince Charles Hosp, Dept Med Imaging, Brisbane, Qld 4032, Australia

[2] Toronto Gen Hosp, Mt Sinai Hosp, Univ Hlth Network, Dept Med Imaging, Toronto, ON, Canada

来源：

AMERICAN JOURNAL OF ROENTGENOLOGY | 2007年 / 189卷 / 06期

关键词：

cardiac imaging; cardiomyopathy; cardiovascular imaging; Fabry's disease; hypertrophic cardiomyopathy; MRI; sarcoidosis; sports medicine;

D O I：

10.2214/AJR.07.2287

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OBJECTIVE. We present a two-part review about the use of MRI in patients with hypertrophic cardiomyopathy (HCM). This article, Part 2, covers the differential diagnosis, risk stratification, and posttreatment MRI follow-up appearances in these patients. CONCLUSION. Cardiovascular MRI is a useful imaging tool for the diagnosis of HCM and follow-up of patients after either surgical myomectomy or septal ablation therapy. In addition, MRI can help to discriminate HCM from the differential diagnoses of other cardiomyopathies and cardiac disorders, and it can potentially identify the subset of patients at risk of sudden cardiac death.

引用

页码：1344 / 1352

页数：9

共 55 条

[1] Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging [J].